A sequential intrastriatal dopaminergic graft strategy in the rodent model for Parkinson's disease: implications for graft survival and targeting.
Optimal placement of intrastriatal dopaminergic grafts is likely crucial to optimize clinical recovery in Parkinson's disease (PD). The target sites of dopaminergic grafts vary among clinical trials and may partially explain the variable results in clinical efficacy reported thus far. In this study we hypothesized that a subsequent dopaminergic graft may promote functional recovery following a suboptimal initial graft. To test this hypothesis, rats with unilateral 6-hydroxydopamine lesions of the right nigrostriatal pathway were randomly divided into three groups. The first group received 900,000 fetal nigral cells in the medial striatum only (n = 6). The second group received 900,000 cells in both the medial and lateral striatum simultaneously (1.8 million total; n = 8). The final group received a second graft of 900,000 cells in the lateral striatum 6 weeks following initial transplantation of a medial graft (n = 6). Amphetamine-induced circling behavior was significantly reduced in both simultaneous and sequential graft groups at 9 and 12 weeks following transplantation of the initial graft. However, no recovery was noted in the single medial graft group at those time points. Furthermore, increased survival of dopaminergic cells was observed in the lateral graft of sequentially grafted animals compared with the medial graft. We conclude that a well-positioned subsequent graft can restore function in animals with a suboptimal initial graft and that the initial graft may improve survival of the second graft. These results are further discussed in relation to their important clinical implication for neural transplantation in PD.
Baker
K A
KA
Department of Anatomy and Neurobiology, Dalhousie University, Halifax, Nova Scotia, Canada.
Purdy
M B
MB
Sadi
D
D
Mukhida
K
K
Mendez
I
I
D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D016380:Brain Tissue Transplantation / Q000379:methods*; D017690:Cell Transplantation; D003342:Corpus Striatum / Q000166:cytology / Q000187:drug effects / Q000601:surgery*; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D016332:Fetal Tissue Transplantation / Q000379:methods*; D006085:Graft Survival; D006801:Humans; D009043:Motor Activity; D009474:Neurons / Q000637:transplantation*; D016627:Oxidopamine / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000601:surgery*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000166:cytology* / Q000196:embryology
D016627:Oxidopamine; D004298:Dopamine